Cargando…

Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines

BACKGROUND: In order to better understand the structural features of natural compounds from traditional Chinese medicines, the scaffold architectures of drug-like compounds in MACCS-II Drug Data Report (MDDR), non-drug-like compounds in Available Chemical Directory (ACD), and natural compounds in Tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Sheng, Li, Youyong, Wang, Junmei, Xu, Xiaojie, Xu, Lei, Wang, Xiaohong, Chen, Lei, Hou, Tingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561156/
https://www.ncbi.nlm.nih.gov/pubmed/23336706
http://dx.doi.org/10.1186/1758-2946-5-5
_version_ 1782257915348910080
author Tian, Sheng
Li, Youyong
Wang, Junmei
Xu, Xiaojie
Xu, Lei
Wang, Xiaohong
Chen, Lei
Hou, Tingjun
author_facet Tian, Sheng
Li, Youyong
Wang, Junmei
Xu, Xiaojie
Xu, Lei
Wang, Xiaohong
Chen, Lei
Hou, Tingjun
author_sort Tian, Sheng
collection PubMed
description BACKGROUND: In order to better understand the structural features of natural compounds from traditional Chinese medicines, the scaffold architectures of drug-like compounds in MACCS-II Drug Data Report (MDDR), non-drug-like compounds in Available Chemical Directory (ACD), and natural compounds in Traditional Chinese Medicine Compound Database (TCMCD) were explored and compared. RESULTS: First, the different scaffolds were extracted from ACD, MDDR and TCMCD by using three scaffold representations, including Murcko frameworks, Scaffold Tree, and ring systems with different complexity and side chains. Then, by examining the accumulative frequency of the scaffolds in each dataset, we observed that the Level 1 scaffolds of the Scaffold Tree offer advantages over the other scaffold architectures to represent the scaffold diversity of the compound libraries. By comparing the similarity of the scaffold architectures presented in MDDR, ACD and TCMCD, structural overlaps were observed not only between MDDR and TCMCD but also between MDDR and ACD. Finally, Tree Maps were used to cluster the Level 1 scaffolds of the Scaffold Tree and visualize the scaffold space of the three datasets. CONCLUSION: The analysis of the scaffold architectures of MDDR, ACD and TCMCD shows that, on average, drug-like molecules in MDDR have the highest diversity while natural compounds in TCMCD have the highest complexity. According to the Tree Maps, it can be observed that the Level 1 scaffolds present in MDDR have higher diversity than those presented in TCMCD and ACD. However, some representative scaffolds in MDDR with high frequency show structural similarities to those in TCMCD and ACD, suggesting that some scaffolds in TCMCD and ACD may be potentially drug-like fragments for fragment-based and de novo drug design.
format Online
Article
Text
id pubmed-3561156
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35611562013-02-05 Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines Tian, Sheng Li, Youyong Wang, Junmei Xu, Xiaojie Xu, Lei Wang, Xiaohong Chen, Lei Hou, Tingjun J Cheminform Research Article BACKGROUND: In order to better understand the structural features of natural compounds from traditional Chinese medicines, the scaffold architectures of drug-like compounds in MACCS-II Drug Data Report (MDDR), non-drug-like compounds in Available Chemical Directory (ACD), and natural compounds in Traditional Chinese Medicine Compound Database (TCMCD) were explored and compared. RESULTS: First, the different scaffolds were extracted from ACD, MDDR and TCMCD by using three scaffold representations, including Murcko frameworks, Scaffold Tree, and ring systems with different complexity and side chains. Then, by examining the accumulative frequency of the scaffolds in each dataset, we observed that the Level 1 scaffolds of the Scaffold Tree offer advantages over the other scaffold architectures to represent the scaffold diversity of the compound libraries. By comparing the similarity of the scaffold architectures presented in MDDR, ACD and TCMCD, structural overlaps were observed not only between MDDR and TCMCD but also between MDDR and ACD. Finally, Tree Maps were used to cluster the Level 1 scaffolds of the Scaffold Tree and visualize the scaffold space of the three datasets. CONCLUSION: The analysis of the scaffold architectures of MDDR, ACD and TCMCD shows that, on average, drug-like molecules in MDDR have the highest diversity while natural compounds in TCMCD have the highest complexity. According to the Tree Maps, it can be observed that the Level 1 scaffolds present in MDDR have higher diversity than those presented in TCMCD and ACD. However, some representative scaffolds in MDDR with high frequency show structural similarities to those in TCMCD and ACD, suggesting that some scaffolds in TCMCD and ACD may be potentially drug-like fragments for fragment-based and de novo drug design. BioMed Central 2013-01-21 /pmc/articles/PMC3561156/ /pubmed/23336706 http://dx.doi.org/10.1186/1758-2946-5-5 Text en Copyright ©2013 Tian et al.; licensee Chemistry Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tian, Sheng
Li, Youyong
Wang, Junmei
Xu, Xiaojie
Xu, Lei
Wang, Xiaohong
Chen, Lei
Hou, Tingjun
Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines
title Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines
title_full Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines
title_fullStr Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines
title_full_unstemmed Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines
title_short Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines
title_sort drug-likeness analysis of traditional chinese medicines: 2. characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional chinese medicines
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561156/
https://www.ncbi.nlm.nih.gov/pubmed/23336706
http://dx.doi.org/10.1186/1758-2946-5-5
work_keys_str_mv AT tiansheng druglikenessanalysisoftraditionalchinesemedicines2characterizationofscaffoldarchitecturesfordruglikecompoundsnondruglikecompoundsandnaturalcompoundsfromtraditionalchinesemedicines
AT liyouyong druglikenessanalysisoftraditionalchinesemedicines2characterizationofscaffoldarchitecturesfordruglikecompoundsnondruglikecompoundsandnaturalcompoundsfromtraditionalchinesemedicines
AT wangjunmei druglikenessanalysisoftraditionalchinesemedicines2characterizationofscaffoldarchitecturesfordruglikecompoundsnondruglikecompoundsandnaturalcompoundsfromtraditionalchinesemedicines
AT xuxiaojie druglikenessanalysisoftraditionalchinesemedicines2characterizationofscaffoldarchitecturesfordruglikecompoundsnondruglikecompoundsandnaturalcompoundsfromtraditionalchinesemedicines
AT xulei druglikenessanalysisoftraditionalchinesemedicines2characterizationofscaffoldarchitecturesfordruglikecompoundsnondruglikecompoundsandnaturalcompoundsfromtraditionalchinesemedicines
AT wangxiaohong druglikenessanalysisoftraditionalchinesemedicines2characterizationofscaffoldarchitecturesfordruglikecompoundsnondruglikecompoundsandnaturalcompoundsfromtraditionalchinesemedicines
AT chenlei druglikenessanalysisoftraditionalchinesemedicines2characterizationofscaffoldarchitecturesfordruglikecompoundsnondruglikecompoundsandnaturalcompoundsfromtraditionalchinesemedicines
AT houtingjun druglikenessanalysisoftraditionalchinesemedicines2characterizationofscaffoldarchitecturesfordruglikecompoundsnondruglikecompoundsandnaturalcompoundsfromtraditionalchinesemedicines